NeoGenomics Inc (NASDAQ:NEO) closed out its 2025 fiscal year by posting fourth-quarter results that narrowly surpassed Wall Street's revenue expectations and delivered a positive earnings surprise. The oncology diagnostics specialist reported sales of $190.2 million for the quarter, a figure that edged out analyst estimates of $189.9 million. More notably, the company's adjusted earnings per share came in at $0.06, solidly beating the consensus forecast of $0.04.
Financial Performance Versus Estimates
The company's top-line growth of 10.6% year-over-year was driven by strong clinical volumes and a continued shift toward higher-value tests, particularly next-generation sequencing (NGS), which grew 23% in the quarter. While the revenue beat was modest, the earnings outperformance suggests improving operational efficiency. The market's initial reaction, however, has been muted to negative in the near term. The stock is down approximately 11% over the past month, indicating that investors may have been anticipating stronger guidance or are weighing the results against a broader market context.
Key Highlights from the Earnings Report
Beyond the headline numbers, the earnings release outlined several critical developments for NeoGenomics:
- Full-Year Growth: Consolidated revenue for 2025 reached $727 million, a 10% increase over the prior year.
- Path to Profitability: The company highlighted a significant reduction in its quarterly net loss, which decreased 36% year-over-year to $10 million. For the full year, however, the net loss widened to $108 million, primarily due to a $27.8 million impairment charge.
- Positive Adjusted EBITDA: A key profitability metric, adjusted EBITDA, turned positive and showed consistent growth, reaching $13 million in Q4 and $43 million for the full year.
- Strong Cash Position: The company ended the quarter with $160 million in cash and cash equivalents.
- Strategic Product Launch: Management emphasized the imminent clinical launch of its RaDaR ST MRD (minimal residual disease) assay, targeting a market it estimates at over $20 billion.
Forward Guidance and Analyst Expectations
Looking ahead, NeoGenomics provided its financial outlook for 2026, which appears to be in close alignment with current analyst expectations. The company guided for full-year revenue between $793 million and $801 million, representing 9-10% growth. The midpoint of this range, $797 million, is nearly identical to the analyst consensus estimate of $803.6 million. The guidance also projects a substantial improvement in net loss, expecting it to narrow to a range of $50-$63 million, and forecasts adjusted EBITDA to grow to $55-$57 million.
For the upcoming first quarter of 2026, analysts are anticipating revenue of approximately $189.3 million. The company's full-year guidance suggests confidence in maintaining its current growth trajectory without a significant acceleration.
Market Reaction and Investor Takeaway
The post-earnings stock performance suggests a "sell the news" dynamic or perhaps investor concern over the pace of margin improvement relative to expectations. While the quarterly EPS beat is a positive signal, the stock's recent decline indicates that the results and guidance may have already been priced in, or that investors are looking for more robust growth projections given the company's investments in new assays like RaDaR ST.
CEO Tony Zook struck an optimistic tone regarding the long-term opportunity in MRD testing, though he cautioned that meaningful revenue contribution from this new segment is not expected until 2027 and beyond. For now, the investment thesis for NeoGenomics continues to hinge on its ability to leverage its community oncology channel leadership, grow its high-value NGS test menu, and steadily march toward sustainable profitability.
For a detailed look at historical earnings, future estimates, and analyst projections, you can review the full earnings data for NeoGenomics Inc here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an endorsement, or a recommendation to buy, sell, or hold any security. Investing involves risk, including the possible loss of principal. Readers should conduct their own research and consult with a qualified financial professional before making any investment decisions.